QUESTIONSSuccessful eCTD Lifecycle Management
Venue: CCT Venues, Canary Wharf
Location: London, United Kingdom
| Event Date/Time: May 27, 2010 | End Date/Time: May 28, 2010 |
Report as SpamDescription
Key Issues to be Discussed at Successful eCTD Lifecycle Management 2010 Include:
*Ensuring eCTD Readiness for Centralised, DCP and MRP Procedures Both Now and in the Future: Roche, H. Lundbeck A/S, Pfizer and Solvay Pharmaceuticals give you insight on the next steps forward and how oyu, as a business can prepare
*Keep in Line with Regulations by Gaining Clarity Over the Current Regulatory Status in Western and Eastern Europe: Gain unprecedented access to 6 key regulatory bodies in order to understand the latest shifts in regulations both now and in the future and get your questions answered
*Successfully Planning for PIM and Transfer of Legacy Products to eCTD To Ensure a Smooth Transition in Preparation for Changes in Guidance: EFPIA discuss the changing landscape for PIM and the steps that need to be taken for you to ensure a smooth transition
*ICH CTD-Q resurrection and new guidance going forward: AstraZeneca show you how to use these Q&A opportunities to your advantage and how to avoid the pitfalls that can occur
*Ensuring eCTD Readiness for Centralised, DCP and MRP Procedures Both Now and in the Future: Roche, H. Lundbeck A/S, Pfizer and Solvay Pharmaceuticals give you insight on the next steps forward and how oyu, as a business can prepare
*Keep in Line with Regulations by Gaining Clarity Over the Current Regulatory Status in Western and Eastern Europe: Gain unprecedented access to 6 key regulatory bodies in order to understand the latest shifts in regulations both now and in the future and get your questions answered
*Successfully Planning for PIM and Transfer of Legacy Products to eCTD To Ensure a Smooth Transition in Preparation for Changes in Guidance: EFPIA discuss the changing landscape for PIM and the steps that need to be taken for you to ensure a smooth transition
*ICH CTD-Q resurrection and new guidance going forward: AstraZeneca show you how to use these Q&A opportunities to your advantage and how to avoid the pitfalls that can occur
